domperidone has been researched along with Canine Diseases in 9 studies
Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.
domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Adverse drug reactions were reported." | 3.30 | A blinded, randomized and controlled multicenter clinical trial to assess the efficacy and safety of Leisguard ( Baxarias, M; Donato, G; Homedes, J; Mateu, C; Miró, G; Pennisi, MG; Salichs, M; Solano-Gallego, L, 2023) |
| "Domperidone has recently been reported to improve kidney function in leishmaniotic dogs affected by CKD." | 3.11 | Efficacy of domperidone plus renal diet in slowing the progression of chronic kidney disease in dogs with leishmaniosis. ( Cavalera, MA; Donghia, R; Gernone, F; Uva, A; Zatelli, A; Zizzadoro, C, 2022) |
| "Domperidone is a dopamine D2 receptor antagonist that has shown to enhance the innate cell-mediated immune response." | 2.79 | A single-centre, open-label, controlled, randomized clinical trial to assess the preventive efficacy of a domperidone-based treatment programme against clinical canine leishmaniasis in a high prevalence area. ( Ferrer, L; Homedes, J; Llinás, J; Sabaté, D; Sust, M, 2014) |
| "Domperidone was effective in controlling and reducing clinical signs and antibody titre." | 2.74 | Use of domperidone in the treatment of canine visceral leishmaniasis: a clinical trial. ( Alvarez, F; Castillo, JA; Couto, CG; Gascón, M; Gómez-Ochoa, P; Zarate, JJ, 2009) |
| "Domperidone treatment has shown to prevent overt disease or improve the clinical condition of infected dogs." | 1.48 | Use of domperidone in canine visceral leishmaniasis: gaps in veterinary knowledge and epidemiological implications. ( Miró, G; Travi, BL, 2018) |
| " This model can be used to identify toxic P-gp substrates with altered safety in dog populations and may reduce dog use in safety studies that are part of the drug approval process." | 1.39 | P-gp substrate-induced neurotoxicity in an Abcb1a knock-in/Abcb1b knock-out mouse model with a mutated canine ABCB1 targeted insertion. ( Buckely, LE; Jhingory, MV; Jones, YL; Lancaster, VA; Myers, MJ; Orzechowski, KL; Robl, MG; Swaim, HL; Swain, MD; Tinaza, CA; Yancy, HF, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cavalera, MA | 1 |
| Gernone, F | 1 |
| Uva, A | 1 |
| Donghia, R | 1 |
| Zizzadoro, C | 1 |
| Zatelli, A | 1 |
| Baxarias, M | 1 |
| Donato, G | 1 |
| Mateu, C | 1 |
| Salichs, M | 1 |
| Homedes, J | 2 |
| Miró, G | 2 |
| Pennisi, MG | 1 |
| Solano-Gallego, L | 1 |
| Paltrinieri, S | 1 |
| Ibba, F | 1 |
| Barbè, F | 1 |
| Rossi, G | 1 |
| Travi, BL | 1 |
| Sabaté, D | 1 |
| Llinás, J | 1 |
| Sust, M | 1 |
| Ferrer, L | 1 |
| Passos, SR | 1 |
| Rodrigues, Tde A | 1 |
| Madureira, AP | 1 |
| Giunchetti, RC | 1 |
| Zanini, MS | 1 |
| Lladró, S | 1 |
| Picado, A | 1 |
| Ballart, C | 1 |
| Portús, M | 1 |
| Gállego, M | 1 |
| Swain, MD | 1 |
| Orzechowski, KL | 1 |
| Swaim, HL | 1 |
| Jones, YL | 1 |
| Robl, MG | 1 |
| Tinaza, CA | 1 |
| Myers, MJ | 1 |
| Jhingory, MV | 1 |
| Buckely, LE | 1 |
| Lancaster, VA | 1 |
| Yancy, HF | 1 |
| Gómez-Ochoa, P | 1 |
| Castillo, JA | 1 |
| Gascón, M | 1 |
| Zarate, JJ | 1 |
| Alvarez, F | 1 |
| Couto, CG | 1 |
4 trials available for domperidone and Canine Diseases
| Article | Year |
|---|---|
Efficacy of domperidone plus renal diet in slowing the progression of chronic kidney disease in dogs with leishmaniosis.
Topics: Animals; Biomarkers; Diet; Dog Diseases; Dogs; Domperidone; Leishmaniasis; Prospective Studies; Rena | 2022 |
A blinded, randomized and controlled multicenter clinical trial to assess the efficacy and safety of Leisguard
Topics: Animals; Antibodies, Protozoan; Dog Diseases; Dogs; Domperidone; Immunotherapy; Leishmania infantum; | 2023 |
A single-centre, open-label, controlled, randomized clinical trial to assess the preventive efficacy of a domperidone-based treatment programme against clinical canine leishmaniasis in a high prevalence area.
Topics: Administration, Oral; Animals; Dog Diseases; Dogs; Domperidone; Dopamine D2 Receptor Antagonists; Im | 2014 |
Use of domperidone in the treatment of canine visceral leishmaniasis: a clinical trial.
Topics: Animals; Antibodies, Protozoan; Antiprotozoal Agents; Dog Diseases; Dogs; Domperidone; Dopamine Anta | 2009 |
5 other studies available for domperidone and Canine Diseases
| Article | Year |
|---|---|
Influence of domperidone supplementation on short-term changes in C-reactive protein and paraoxonase-1 in dogs with leishmaniasis undergoing meglumine antimoniate and allopurinol therapy.
Topics: Allopurinol; Animals; Aryldialkylphosphatase; C-Reactive Protein; Dietary Supplements; Dog Diseases; | 2020 |
Use of domperidone in canine visceral leishmaniasis: gaps in veterinary knowledge and epidemiological implications.
Topics: Animals; Dog Diseases; Dogs; Domperidone; Dopamine Antagonists; Leishmania infantum; Leishmaniasis, | 2018 |
Clinical treatment of cutaneous leishmaniasis in dogs with furazolidone and domperidone.
Topics: Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Domperidone; Female; Furazolidone; Leishmania bra | 2014 |
Management, prevention and treatment of canine leishmaniosis in north-eastern Spain: an online questionnaire-based survey in the province of Girona with special emphasis on new preventive methods (CaniLeish vaccine and domperidone).
Topics: Animals; Dog Diseases; Dogs; Domperidone; Humans; Internet; Leishmaniasis; Leishmaniasis Vaccines; S | 2017 |
P-gp substrate-induced neurotoxicity in an Abcb1a knock-in/Abcb1b knock-out mouse model with a mutated canine ABCB1 targeted insertion.
Topics: Animals; Anti-Infective Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette | 2013 |